Sanofi Publishes Revised Financial Statements Excluding Opella

Sanofi, the global healthcare leader, has released its revised financial statements reflecting its new business scope excluding Opella, its consumer healthcare division. This follows a prior announcement regarding the transfer of a 50% controlling stake in Opella to CD&R. The updated financial data is now accessible on Sanofi's investor website and aligns with its strategic transition towards a more focused biopharma company.

The adjustment marks Opella's classification as a discontinued operation, influencing all financial reports from 2023 through 2024. Sanofi's recent financial revisions, reviewed by their auditors, include updated sales figures, net income, and IFRS financials.

The forthcoming Q4 2024 results, which reflect this new scope, are scheduled for release on January 30, 2025, offering stakeholders fresh insights into Sanofi's streamlined operations.